These are top 10 stocks traded on the Robinhood UK platform in July
Edward C. Fargis, Executive Vice President and General Counsel at Privia Health Group , Inc. (NASDAQ:PRVA), a $2.9 billion healthcare company with a GREAT financial health score according to InvestingPro, recently executed stock sales totaling $120,255. The transactions, disclosed in a Form 4 filing with the Securities and Exchange Commission, occurred over two days in March.
On March 10, Fargis sold 2,529 shares at a price of $24.53 each. The following day, he sold an additional 2,438 shares at $23.88 per share. These transactions were part of a nondiscretionary sale to cover tax obligations related to the vesting of restricted stock units. The stock has shown strong momentum, gaining over 27% in the past six months, with analysts setting price targets ranging from $21 to $40.
Following these sales, Fargis retains ownership of 93,054 shares in the company. For deeper insights into insider trading patterns and comprehensive analysis, access the full Pro Research Report available on InvestingPro.
In other recent news, Privia Health Group has made notable adjustments to its executive compensation structure, as detailed in a recent SEC filing. Parth Mehrotra, whose specific role was not disclosed, will receive an annual base salary of $650,000, with eligibility for a performance bonus up to 125% of his base salary and an annual long-term incentive award valued at $8,000,000 starting in 2025. Analysts have also been active in revising their outlook on Privia Health. Jefferies raised its price target to $29, maintaining a Buy rating, citing the company’s strong cash generation and minimal regulatory exposure. Canaccord Genuity increased its target to $30, praising Privia’s consistent performance and prudent growth strategy. JMP Securities lifted its target to $29, highlighting the company’s robust guidance for 2025, which aligns with consensus estimates. Piper Sandler made a significant adjustment, raising the price target to $40, recognizing Privia’s strategic approach to value-based care and its stable growth trajectory. These developments reflect analysts’ confidence in Privia Health’s financial health and strategic positioning in the healthcare industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.